Carcinoma, Neuroendocrine
Information
- Disease name
- Carcinoma, Neuroendocrine
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02487095 | Active, not recruiting | Phase 1/Phase 2 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | July 30, 2015 | October 30, 2025 |
| NCT00511862 | Completed | Phase 2 | TheraSphere for the Treatment of Liver Metastases | January 2007 | March 2011 |
| NCT02205515 | Completed | Phase 1/Phase 2 | An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | March 2016 | October 2021 |
| NCT02250885 | Completed | Phase 2 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | August 2014 | August 2016 |
| NCT00353015 | Completed | Phase 2 | Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract | March 2003 | July 2009 |
| NCT03012620 | Completed | Phase 2 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | July 5, 2017 | December 14, 2023 |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT06406465 | Not yet recruiting | Phase 2 | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | June 23, 2024 | July 30, 2028 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT01876771 | Recruiting | Phase 2 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | April 29, 2014 | December 2033 |
| NCT06041516 | Recruiting | Phase 1 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | June 23, 2024 | October 30, 2029 |
| NCT05461430 | Recruiting | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | July 15, 2022 | July 2026 | |
| NCT02754297 | Recruiting | Phase 2 | Personalized PRRT of Neuroendocrine Tumors | April 12, 2016 | April 12, 2029 |
| NCT05237934 | Recruiting | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | April 25, 2022 | December 31, 2032 | |
| NCT04488263 | Terminated | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | November 24, 2020 | January 11, 2023 | |
| NCT02315625 | Terminated | Phase 2 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | April 8, 2015 | May 22, 2019 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018278